3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
3
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
pembrolizumab
21
Cyclophosphamide
18
fludarabine
8
Radiotherapy
8
Radiosurgery
7
Nivolumab
7
poly ICLC
6
fludarabine phosphate
6
aldesleukin
6
Therapeutics
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
durvalumab
5
Psychiatric Rehabilitation
5
Interleukin-2
5
Drug Therapy
5
Docetaxel
5
Cisplatin
5
temsirolimus
4
cemiplimab
4
Trastuzumab
4
Temozolomide
4
Sirolimus
4
Gemcitabine
4
Flow Cytometry
4
Filgrastim
4
Carboplatin
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Ramucirumab
×
Dermatologic
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled